C4 Therapeutics, a clinical-stage biopharmaceutical company, detailed strategic milestones through 2028.
They highlighted the advancement of cemsidomide as a potential best-in-class IKZF1/3 degrader and a focused discovery strategy on novel targets.
Trials for cemsidomide are on track, with the Phase 2 MOMENTUM trial set to begin in Q1 2026.
Cemsidomide Trials Progress
Initiate Phase 2 MOMENTUM trial in Q1 2026 and Phase 1b trial in Q2 2026, exploring combinations with other therapies.
Internal Discovery Strategy
Focused on inflammation, neuro-inflammation, and neuro-degenerative diseases with novel targets in validated pathways.
Financial Position
Cash runway extends to the end of 2028, providing funding through key milestones.
- C4T aims to become a fully integrated biopharmaceutical company leveraging targeted protein degradation for breakthrough therapies.
- The company's strong balance sheet ensures continued progress in advancing their portfolio and creating transformative medicines.
C4 Therapeutics demonstrates a strong commitment to advancing cemsidomide and pioneering therapies for challenging diseases.